ScholarIQanswers from OpenAlex & ORCID
Karl D. Lewis
ResearcherPublications, citations & collaboration network
Karl D. Lewis is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Karl D. Lewis have?
ScholarIQindexed works
Karl D. Lewis has 350 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Karl D. Lewis have?
ScholarIQcitation count
Karl D. Lewis has 28,338 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Karl D. Lewis?
ScholarIQh-index
Karl D. Lewis has an h-index of 61 in OpenAlex.
What is the i10-index of Karl D. Lewis?
ScholarIQi10-index
Karl D. Lewis has an i10-index of 144 in OpenAlex.
What is the ORCID of Karl D. Lewis?
ScholarIQorcid
The ORCID for Karl D. Lewis is on the source record.
What is the OpenAlex record for Karl D. Lewis?
ScholarIQopenalex
The OpenAlex for Karl D. Lewis is on the source record.
What are the most-cited papers on Karl D. Lewis?
ScholarIQmost cited works
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro, Luc Dirix, Karl D. Lewis, John D. Hainsworth, James Solomon, Simon Yoo, Sarah T. Arron, Philip Friedlander, Ellen S. Marmur, Charles M. Rudin, Anne Lynn S. Chang, Jennifer A. Low, Howard Mackey, Robert L. Yauch, Richard Graham, Josina C. Reddy, Axel Hauschild
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D. Lewis, P. Combemale, R. M. Herd, Ragini R. Kudchadkar, Uwe Trefzer, Sven Gogov, Céline Pallaud, Tingting Yi, Manisha Mone, Martin Kaatz, Carmen Loquai, Alexander Stratigos, H. J. Schulze, Ruth Plummer, Anne Lynn S. Chang, Frank Cornélis, John T. Lear, Dalila Sellami, Reinhard Dummer
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo‐Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey S. Weber, Andrew J.S. Furness, Nikhil I. Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A. Sarnaik